114 related articles for article (PubMed ID: 38520670)
21. A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.
Davis KL; Fox E; Isikwei E; Reid JM; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
Clin Cancer Res; 2022 Dec; 28(23):5088-5097. PubMed ID: 36190525
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Okada K; Yamasaki K; Tanaka C; Fujisaki H; Osugi Y; Hara J
Jpn J Clin Oncol; 2013 Nov; 43(11):1073-9. PubMed ID: 24002900
[TBL] [Abstract][Full Text] [Related]
23. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.
Weigel B; Malempati S; Reid JM; Voss SD; Cho SY; Chen HX; Krailo M; Villaluna D; Adamson PC; Blaney SM
Pediatr Blood Cancer; 2014 Mar; 61(3):452-6. PubMed ID: 23956055
[TBL] [Abstract][Full Text] [Related]
25. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).
Thompson PA; Drissi R; Muscal JA; Panditharatna E; Fouladi M; Ingle AM; Ahern CH; Reid JM; Lin T; Weigel BJ; Blaney SM
Clin Cancer Res; 2013 Dec; 19(23):6578-84. PubMed ID: 24097866
[TBL] [Abstract][Full Text] [Related]
26. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.
Jacobs S; Fox E; Krailo M; Hartley G; Navid F; Wexler L; Blaney SM; Goodwin A; Goodspeed W; Balis FM; Adamson PC; Widemann BC
Clin Cancer Res; 2010 Jan; 16(2):750-4. PubMed ID: 20068084
[TBL] [Abstract][Full Text] [Related]
28. A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.
Pilbeam KL; Pradhan K; Croop J; Minard CG; Liu X; Voss SD; Isikwei E; Berg SL; Reid JM; Fox E; Weigel BJ
Pediatr Blood Cancer; 2024 Mar; 71(3):e30817. PubMed ID: 38189770
[TBL] [Abstract][Full Text] [Related]
29. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)
Gaspar N; Campbell-Hewson Q; Gallego Melcon S; Locatelli F; Venkatramani R; Hecker-Nolting S; Gambart M; Bautista F; Thebaud E; Aerts I; Morland B; Rossig C; Canete Nieto A; Longhi A; Lervat C; Entz-Werle N; Strauss SJ; Marec-Berard P; Okpara CE; He C; Dutta L; Casanova M
ESMO Open; 2021 Oct; 6(5):100250. PubMed ID: 34562750
[TBL] [Abstract][Full Text] [Related]
30. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
31. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
32. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
Trippett TM; Herzog C; Whitlock JA; Wolff J; Kuttesch J; Bagatell R; Hunger SP; Boklan J; Smith AA; Arceci RJ; Katzenstein HM; Harbison C; Zhou X; Lu H; Langer C; Weber M; Gore L
J Clin Oncol; 2009 Oct; 27(30):5102-8. PubMed ID: 19770383
[TBL] [Abstract][Full Text] [Related]
33. A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory
Kieran MW; Geoerger B; Dunkel IJ; Broniscer A; Hargrave D; Hingorani P; Aerts I; Bertozzi AI; Cohen KJ; Hummel TR; Shen V; Bouffet E; Pratilas CA; Pearson ADJ; Tseng L; Nebot N; Green S; Russo MW; Whitlock JA
Clin Cancer Res; 2019 Dec; 25(24):7294-7302. PubMed ID: 31506385
[TBL] [Abstract][Full Text] [Related]
34. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors.
Cohen EEW; Pishvaian MJ; Shepard DR; Wang D; Weiss J; Johnson ML; Chung CH; Chen Y; Huang B; Davis CB; Toffalorio F; Thall A; Powell SF
J Immunother Cancer; 2019 Dec; 7(1):342. PubMed ID: 31801624
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
Pinto N; DuBois SG; Marachelian A; Diede SJ; Taraseviciute A; Glade Bender JL; Tsao-Wei D; Groshen SG; Reid JM; Haas-Kogan DA; Reynolds CP; Kang MH; Irwin MS; Macy ME; Villablanca JG; Matthay KK; Park JR
Pediatr Blood Cancer; 2018 Jul; 65(7):e27023. PubMed ID: 29603591
[TBL] [Abstract][Full Text] [Related]
36. A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors.
Doi T; Aramaki T; Yasui H; Muro K; Ikeda M; Okusaka T; Inaba Y; Nakai K; Ikezawa H; Nakajima R
Invest New Drugs; 2019 Oct; 37(5):1061-1074. PubMed ID: 30623276
[TBL] [Abstract][Full Text] [Related]
37. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Jakacki RI; Hamilton M; Gilbertson RJ; Blaney SM; Tersak J; Krailo MD; Ingle AM; Voss SD; Dancey JE; Adamson PC
J Clin Oncol; 2008 Oct; 26(30):4921-7. PubMed ID: 18794549
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study.
Blaney SM; Needle MN; Gillespie A; Sato JK; Reaman GH; Berg SL; Adamson PC; Krailo MD; Bleyer WA; Poplack DG; Balis FM
Clin Cancer Res; 1998 Feb; 4(2):357-60. PubMed ID: 9516923
[TBL] [Abstract][Full Text] [Related]
39. Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report.
Leary SES; Park JR; Reid JM; Ralya AT; Baruchel S; Wu B; Roberts TPL; Liu X; Minard CG; Fox E; Weigel B; Blaney S
Clin Cancer Res; 2017 Oct; 23(20):6062-6069. PubMed ID: 28751444
[No Abstract] [Full Text] [Related]
40. Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study.
Trippett T; Toledano H; Campbell Hewson Q; Verschuur A; Langevin AM; Aerts I; Howell L; Gallego S; Rossig C; Smith A; Patel D; Pereira LR; Cheeti S; Musib L; Hutchinson KE; Devlin C; Bernardi R; Geoerger B
Target Oncol; 2022 May; 17(3):283-293. PubMed ID: 35715627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
